B+
Bull case
30%
Probability
Target price
$10.00
+203.0% vs current
LRMR
Larimar TherapeuticsDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
40%
Probability
Target price
$5.20
+57.6% vs current
B-
Bear case
30%
Probability
Target price
$2.20
-33.3% vs current
AI sentiment snapshot
Latest data as of 2026-04-29
Recent news sentiment (30D)
+0.2
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+100.0
Score
AI commentary
Primary-source evidence still supports a cautious monitoring view rather than a high-conviction long. The latest verified company source set in the packet is the March 19, 2026 SEC filing group, which reinforced Q2 2026 topline data, June 2026 BLA timing, and runway into Q2 2027 [#8-K-2026-03-19][#10-K-2026-03-19]. However, the queued post-earnings follow-up cites April 28, 2026, and no newer company earnings release, transcript, consensus surprise, or analyst revision set was confirmed in the packet; that missing T+3 earnings evidence keeps confidence capped even though recent headlines have been constructive.
RankAlpha Sentiment Codex - 2026-04-29
Open full AI memoEvidence flagged
Coverage is limited for this name. This memo is usable, but confidence is lower and evidence depth is thinner than a standard report.
Impact
tentative
Confidence
-
AI events
2026-06-15eventQ2 2026 open-label topline data is the next real de-risking checkpointHigh impact
Larimar said topline open-label study data intended to support the nomlabofusp BLA is expected in Q2 2026, and the March 19, 2026 company update kept that timing in place; a clean data package would help the regulatory case, while any slippage or mixed efficacy/safety readthrough would likely pressure the stock [#8-K-2026-03-19][#10-K-2026-03-19].
2026-06-30eventJune 2026 BLA submission remains the core binary regulatory eventHigh impact
Management reiterated that the nomlabofusp BLA seeking accelerated approval is on track for June 2026, but prior company disclosures also make clear that FDA review still governs whether the package is accepted and whether the safety database is sufficient at filing and review [#8-K-2026-03-19][#10-K-2026-03-19].
2027-06-30catalystCash runway appears to cover the BLA window, but not all downstream execution riskHigh impact
Larimar reported $244.5 million of pro forma cash after the February 2026 financing and projected runway into Q2 2027, which should fund the planned BLA and early confirmatory-study setup, but the company remains a cash-burning single-asset biotech and could still need more capital if timelines slip or commercialization spending rises [#8-K-2026-03-19][#10-K-2026-03-19].
Recommendation
N/A
No formal recommendation provided.
As of 2026-04-29 • Updated nightlySource: Internal modelMethodology